{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T13:26:06Z","timestamp":1783776366339,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Australian Government Research Training Program Scholarship"},{"name":"Australian National Health and Medical Research Council","award":["Investigator Grant #2016792"],"award-info":[{"award-number":["Investigator Grant #2016792"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-97282-y","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T08:59:11Z","timestamp":1744793951000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Transmissibility of a new Plasmodium falciparum 3D7 bank for use in malaria volunteer infection studies evaluating transmission blocking interventions"],"prefix":"10.1038","volume":"15","clinical-trial-number":[{"clinical-trial-number":"actrn12622001097730","registry":"10.18810\/anzctr"}],"author":[{"given":"Sean A.","family":"Lynch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azrin N.","family":"Abd-Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny M.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanita M.","family":"Heunis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"S.E. Gower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Potter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Jennings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Mathison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nischal","family":"Sahai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona H.","family":"Amante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget E.","family":"Barber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"97282_CR1","unstructured":"WHO. World Malaria Report 2024. (World Health Organization, 2024)."},{"key":"97282_CR2","unstructured":"WHO. Global Malaria Programme operational strategy 2024\u20132030. (World Health Organization, 2024)."},{"key":"97282_CR3","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41573-023-00772-9","volume":"22","author":"JL Siqueira-Neto","year":"2023","unstructured":"Siqueira-Neto, J. L. et al. Antimalarial drug discovery: Progress and approaches. Nat. Rev. Drug Discov. 22, 807\u2013826. https:\/\/doi.org\/10.1038\/s41573-023-00772-9 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"97282_CR4","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/S1473-3099(15)00479-X","volume":"16","author":"A Dicko","year":"2016","unstructured":"Dicko, A. et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: A single-blind, dose-ranging, adaptive randomised phase 2 trial. Lancet Infect. Dis 16, 674\u2013684. https:\/\/doi.org\/10.1016\/S1473-3099(15)00479-X (2016).","journal-title":"Lancet Infect. Dis"},{"key":"97282_CR5","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S1473-3099(18)30044-6","volume":"18","author":"A Dicko","year":"2018","unstructured":"Dicko, A. et al. Efficacy and safety of primaquine and methylene blue for prevention of Plasmodium falciparum transmission in Mali: A phase 2, single-blind, randomised controlled trial. Lancet Infect. Dis 18, 627\u2013639. https:\/\/doi.org\/10.1016\/S1473-3099(18)30044-6 (2018).","journal-title":"Lancet Infect. Dis"},{"key":"97282_CR6","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S2666-5247(24)00023-5","volume":"5","author":"A Mahamar","year":"2024","unstructured":"Mahamar, A. et al. Artemether\u2013lumefantrine with or without single-dose primaquine and sulfadoxine\u2013pyrimethamine plus amodiaquine with or without single-dose tafenoquine to reduce Plasmodium falciparum transmission: A phase 2, single-blind, randomised clinical trial in Ouelessebougou, Mali. The Lancet Microbe 5, 633\u2013644. https:\/\/doi.org\/10.1016\/S2666-5247(24)00023-5 (2024).","journal-title":"The Lancet Microbe"},{"key":"97282_CR7","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1016\/S2666-5247(21)00192-0","volume":"3","author":"W Stone","year":"2022","unstructured":"Stone, W. et al. Pyronaridine\u2013artesunate or dihydroartemisinin\u2013piperaquine combined with single low-dose primaquine to prevent Plasmodium falciparum malaria transmission in Ou\u00e9less\u00e9bougou, Mali: A four-arm, single-blind, phase 2\/3, randomised trial. The Lancet Microbe 3, e41\u2013e51. https:\/\/doi.org\/10.1016\/S2666-5247(21)00192-0 (2022).","journal-title":"The Lancet Microbe"},{"key":"97282_CR8","doi-asserted-by":"publisher","first-page":"e336","DOI":"10.1016\/S2666-5247(21)00356-6","volume":"3","author":"W Stone","year":"2022","unstructured":"Stone, W. et al. Single low-dose tafenoquine combined with dihydroartemisinin\u2013piperaquine to reduce Plasmodium falciparum transmission in Ouelessebougou, Mali: A phase 2, single-blind, randomised clinical trial. The Lancet Microbe 3, e336\u2013e347. https:\/\/doi.org\/10.1016\/S2666-5247(21)00356-6 (2022).","journal-title":"The Lancet Microbe"},{"key":"97282_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1128\/cmr.00025-08","volume":"22","author":"DL Doolan","year":"2009","unstructured":"Doolan, D. L., Doba\u00f1o, C. & Baird, J. K. Acquired immunity to malaria. Clin. Microbiol. Rev. 22, 13\u201336. https:\/\/doi.org\/10.1128\/cmr.00025-08 (2009).","journal-title":"Clin. Microbiol. Rev."},{"key":"97282_CR10","doi-asserted-by":"publisher","first-page":"e00626","DOI":"10.7554\/eLife.00626","volume":"2","author":"TS Churcher","year":"2013","unstructured":"Churcher, T. S. et al. Predicting mosquito infection from Plasmodium falciparum gametocyte density and estimating the reservoir of infection. Elife 2, e00626. https:\/\/doi.org\/10.7554\/eLife.00626 (2013).","journal-title":"Elife"},{"key":"97282_CR11","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s13063-018-2563-1","volume":"19","author":"G Mtove","year":"2018","unstructured":"Mtove, G. et al. Multiple-level stakeholder engagement in malaria clinical trials: Addressing the challenges of conducting clinical research in resource-limited settings. Trials 19, 190. https:\/\/doi.org\/10.1186\/s13063-018-2563-1 (2018).","journal-title":"Trials"},{"key":"97282_CR12","doi-asserted-by":"publisher","DOI":"10.1128\/iai.00479-17","author":"DI Stanisic","year":"2017","unstructured":"Stanisic, D. I., McCarthy, J. S. & Good, M. F. Controlled human malaria infection: Applications, advances, and challenges. Infect. Immun. https:\/\/doi.org\/10.1128\/iai.00479-17 (2017).","journal-title":"Infect. Immun."},{"key":"97282_CR13","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1093\/cid\/ciad075","volume":"76","author":"BE Barber","year":"2023","unstructured":"Barber, B. E. et al. Characterizing the blood-stage antimalarial activity of tafenoquine in healthy volunteers experimentally infected with Plasmodium falciparum. Clin. Infect. Dis. 76, 1919\u20131927. https:\/\/doi.org\/10.1093\/cid\/ciad075 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"97282_CR14","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S1473-3099(21)00679-4","volume":"22","author":"BE Barber","year":"2022","unstructured":"Barber, B. E. et al. Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: A first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection study. Lancet Infect. Dis. 22, 879\u2013890. https:\/\/doi.org\/10.1016\/S1473-3099(21)00679-4 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"97282_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107196","volume":"64","author":"BE Barber","year":"2024","unstructured":"Barber, B. E. et al. Characterising the blood-stage antimalarial activity of pyronaridine in healthy volunteers experimentally infected with Plasmodium falciparum. Int. J. Antimicrob. Agents 64, 107196. https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107196 (2024).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"97282_CR16","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01371-19","author":"JS McCarthy","year":"2019","unstructured":"McCarthy, J. S. et al. A single-dose combination study with the experimental antimalarials artefenomel and DSM265 to determine safety and antimalarial activity against blood-stage Plasmodium falciparum in healthy volunteers. Antimicrob. Agents Chemother. https:\/\/doi.org\/10.1128\/aac.01371-19 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"97282_CR17","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1172\/jci98012","volume":"128","author":"KA Collins","year":"2018","unstructured":"Collins, K. A. et al. A controlled human malaria infection model enabling evaluation of transmission-blocking interventions. J. Clin. Invest. 128, 1551\u20131562. https:\/\/doi.org\/10.1172\/jci98012 (2018).","journal-title":"J. Clin. Invest."},{"key":"97282_CR18","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1093\/cid\/ciac503","volume":"76","author":"R Webster","year":"2023","unstructured":"Webster, R. et al. Transmission blocking activity of low-dose tafenoquine in healthy volunteers experimentally infected with Plasmodium falciparum. Clin. Infect. Dis. 76, 506\u2013512. https:\/\/doi.org\/10.1093\/cid\/ciac503 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"97282_CR19","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1093\/infdis\/jiaa157","volume":"224","author":"M Alkema","year":"2020","unstructured":"Alkema, M. et al. A randomized clinical trial to compare Plasmodium falciparum gametocytemia and infectivity after blood-stage or mosquito bite-induced controlled malaria infection. J. Infect. Dis. 224, 1257\u20131265. https:\/\/doi.org\/10.1093\/infdis\/jiaa157 (2020).","journal-title":"J. Infect. Dis."},{"key":"97282_CR20","doi-asserted-by":"publisher","first-page":"495","DOI":"10.4269\/ajtmh.1997.57.495","volume":"57","author":"Q Cheng","year":"1997","unstructured":"Cheng, Q., Lawrence, G., Reed, C., Stowers, A. & Ranford-Cartwright, L. Measurement of Plasmodium falciparum growth rates in vivo: A test of malaria vaccines. Am. J. Trop. Med. Hyg. 57, 495\u2013500 (1997).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"97282_CR21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12936-021-03627-z","volume":"20","author":"SD Woolley","year":"2021","unstructured":"Woolley, S. D. et al. Development and evaluation of a new Plasmodium falciparum 3D7 blood stage malaria cell bank for use in malaria volunteer infection studies. Malar. J. 20, 93. https:\/\/doi.org\/10.1186\/s12936-021-03627-z (2021).","journal-title":"Malar. J."},{"key":"97282_CR22","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1016\/S0264-410X(99)00444-2","volume":"18","author":"G Lawrence","year":"2000","unstructured":"Lawrence, G. et al. Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers. Vaccine 18, 1925\u20131931. https:\/\/doi.org\/10.1016\/S0264-410X(99)00444-2 (2000).","journal-title":"Vaccine"},{"key":"97282_CR23","doi-asserted-by":"publisher","first-page":"41303","DOI":"10.1038\/srep41303","volume":"7","author":"A Claessens","year":"2017","unstructured":"Claessens, A., Affara, M., Assefa, S. A., Kwiatkowski, D. P. & Conway, D. J. Culture adaptation of malaria parasites selects for convergent loss-of-function mutants. Sci. Rep. 7, 41303. https:\/\/doi.org\/10.1038\/srep41303 (2017).","journal-title":"Sci. Rep."},{"key":"97282_CR24","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nature12920","volume":"507","author":"BFC Kafsack","year":"2014","unstructured":"Kafsack, B. F. C. et al. A transcriptional switch underlies commitment to sexual development in malaria parasites. Nature 507, 248\u2013252. https:\/\/doi.org\/10.1038\/nature12920 (2014).","journal-title":"Nature"},{"key":"97282_CR25","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ebiom.2019.09.001","volume":"48","author":"R Hoo","year":"2019","unstructured":"Hoo, R. et al. Transcriptome profiling reveals functional variation in Plasmodium falciparum parasites from controlled human malaria infection studies. EBioMedicine 48, 442\u2013452. https:\/\/doi.org\/10.1016\/j.ebiom.2019.09.001 (2019).","journal-title":"EBioMedicine"},{"key":"97282_CR26","doi-asserted-by":"publisher","first-page":"e03820","DOI":"10.1128\/spectrum.03820-22","volume":"11","author":"JA Kengne-Ouafo","year":"2023","unstructured":"Kengne-Ouafo, J. A. et al. The global transcriptome of Plasmodium falciparum mid-stage gametocytes (stages II\u2013IV) appears largely conserved and gametocyte-specific gene expression patterns vary in clinical isolates. Microbiol. Spectr. 11, e03820\u2013e03822. https:\/\/doi.org\/10.1128\/spectrum.03820-22 (2023).","journal-title":"Microbiol. Spectr."},{"key":"97282_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000644","volume":"5","author":"MJ Mackinnon","year":"2009","unstructured":"Mackinnon, M. J. et al. Comparative transcriptional and genomic analysis of Plasmodium falciparum field isolates. PLoS Pathog. 5, e1000644 (2009).","journal-title":"PLoS Pathog."},{"key":"97282_CR28","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1475-2875-10-48","volume":"10","author":"RJ Rockett","year":"2011","unstructured":"Rockett, R. J. et al. A real-time, quantitative PCR method using hydrolysis probes for the monitoring of Plasmodium falciparum load in experimentally infected human volunteers. Malar. J. 10, 48. https:\/\/doi.org\/10.1186\/1475-2875-10-48 (2011).","journal-title":"Malar. J."},{"key":"97282_CR29","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/infdis\/jiw128","volume":"214","author":"CJ Pasay","year":"2016","unstructured":"Pasay, C. J. et al. Piperaquine monotherapy of drug-susceptible Plasmodium falciparum Infection results in rapid clearance of parasitemia but is followed by the appearance of gametocytemia. J. Infect. Dis. 214, 105\u2013113. https:\/\/doi.org\/10.1093\/infdis\/jiw128 (2016).","journal-title":"J. Infect. Dis."},{"key":"97282_CR30","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s12936-020-03291-9","volume":"19","author":"CYT Wang","year":"2020","unstructured":"Wang, C. Y. T. et al. Assays for quantification of male and female gametocytes in human blood by qRT-PCR in the absence of pure sex-specific gametocyte standards. Malar. J. 19, 218. https:\/\/doi.org\/10.1186\/s12936-020-03291-9 (2020).","journal-title":"Malar. J."},{"key":"97282_CR31","doi-asserted-by":"publisher","first-page":"188","DOI":"10.4269\/ajtmh.16-0893","volume":"97","author":"FG Tadesse","year":"2017","unstructured":"Tadesse, F. G. et al. Molecular markers for sensitive detection of Plasmodium falciparum asexual stage parasites and their application in a malaria clinical trial. Am. J. Trop. Med. Hyg. 97, 188\u2013198. https:\/\/doi.org\/10.4269\/ajtmh.16-0893 (2017).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"97282_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2017.00456","author":"JZ Bakdash","year":"2017","unstructured":"Bakdash, J. Z. & Marusich, L. R. Repeated measures correlation. Front. Psychol. https:\/\/doi.org\/10.3389\/fpsyg.2017.00456 (2017).","journal-title":"Front. Psychol."},{"key":"97282_CR33","doi-asserted-by":"publisher","unstructured":"Abd-Rahman, A. N. et al. Characterizing the pharmacological interaction of the antimalarial combination artefenomel\u2013piperaquine in healthy volunteers with induced blood stage Plasmodium falciparum. medRxiv, 2024.2002.2007.24302432, https:\/\/doi.org\/10.1101\/2024.02.07.24302432 (2024).","DOI":"10.1101\/2024.02.07.24302432"},{"key":"97282_CR34","doi-asserted-by":"publisher","unstructured":"Pava, Z. et al. Plasmodium falciparum artemisinin-resistant K13 mutations confer a sexual-stage transmission advantage that can be overcome with atovaquone-proguanil. medRxiv, 2020.2010.2026.20214619, https:\/\/doi.org\/10.1101\/2020.10.26.20214619 (2020).","DOI":"10.1101\/2020.10.26.20214619"},{"key":"97282_CR35","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41579-024-01008-2","volume":"22","author":"PJ Rosenthal","year":"2024","unstructured":"Rosenthal, P. J., Asua, V. & Conrad, M. D. Emergence, transmission dynamics and mechanisms of artemisinin partial resistance in malaria parasites in Africa. Nat. Rev. Microbiol. 22, 373\u2013384. https:\/\/doi.org\/10.1038\/s41579-024-01008-2 (2024).","journal-title":"Nat. Rev. Microbiol."},{"key":"97282_CR36","unstructured":"WHO. Policy brief on single-dose primaquine as a gametocytocide in Plasmodium falciparum malaria. (World Health Organization, 2015)."},{"key":"97282_CR37","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1093\/cid\/ciz134","volume":"69","author":"J Bradley","year":"2019","unstructured":"Bradley, J. et al. Transmission-blocking effects of primaquine and methylene blue suggest Plasmodium falciparum gametocyte sterilization rather than effects on sex ratio. Clin. Infect. Dis. 69, 1436\u20131439. https:\/\/doi.org\/10.1093\/cid\/ciz134 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"97282_CR38","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1473-3099(12)70198-6","volume":"13","author":"NJ White","year":"2013","unstructured":"White, N. J. Primaquine to prevent transmission of falciparum malaria. Lancet Infect. Dis 13, 175\u2013181. https:\/\/doi.org\/10.1016\/S1473-3099(12)70198-6 (2013).","journal-title":"Lancet Infect. Dis"},{"key":"97282_CR39","doi-asserted-by":"publisher","unstructured":"Mahamar, A. et al. Artemether\u2013lumefantrine\u2013amodiaquine or artesunate\u2013amodiaquine combined with single low-dose primaquine to reduce Plasmodium falciparum malaria transmission in Ou\u00e9less\u00e9bougou, Mali: A five-arm, phase 2, single-blind, randomised clinical trial. medRxiv, 2024.2002.2023.24303266, https:\/\/doi.org\/10.1101\/2024.02.23.24303266 (2024).","DOI":"10.1101\/2024.02.23.24303266"},{"key":"97282_CR40","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/S1473-3099(21)00072-4","volume":"21","author":"C Andolina","year":"2021","unstructured":"Andolina, C. et al. Sources of persistent malaria transmission in a setting with effective malaria control in eastern Uganda: A longitudinal, observational cohort study. Lancet Infect. Dis 21, 1568\u20131578. https:\/\/doi.org\/10.1016\/S1473-3099(21)00072-4 (2021).","journal-title":"Lancet Infect. Dis"},{"key":"97282_CR41","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1038\/s41467-021-22573-7","volume":"12","author":"A Barry","year":"2021","unstructured":"Barry, A. et al. Higher gametocyte production and mosquito infectivity in chronic compared to incident Plasmodium falciparum infections. Nat. Commun. 12, 2443. https:\/\/doi.org\/10.1038\/s41467-021-22573-7 (2021).","journal-title":"Nat. Commun."},{"key":"97282_CR42","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s13071-023-05761-w","volume":"16","author":"LM Hofer","year":"2023","unstructured":"Hofer, L. M. et al. Malaria rapid diagnostic tests reliably detect asymptomatic Plasmodium falciparum infections in school-aged children that are infectious to mosquitoes. Parasit. Vectors 16, 217. https:\/\/doi.org\/10.1186\/s13071-023-05761-w (2023).","journal-title":"Parasit. Vectors"},{"key":"97282_CR43","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/s41467-021-21269-2","volume":"12","author":"KM Sumner","year":"2021","unstructured":"Sumner, K. M. et al. Genotyping cognate Plasmodium falciparum in humans and mosquitoes to estimate onward transmission of asymptomatic infections. Nat. Commun. 12, 909. https:\/\/doi.org\/10.1038\/s41467-021-21269-2 (2021).","journal-title":"Nat. Commun."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97282-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97282-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97282-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T08:59:17Z","timestamp":1744793957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97282-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["97282"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-97282-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"3 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13094"}}